Integration of azithromycin mass administration to 1–11-month-old children into an existing health platform to reduce child mortality: a cluster-randomised trial in Burkina Faso

Background Azithromycin mass drug administration (MDA) to ages 1–59 months can reduce childhood mortality; however, more evidence is needed to support targeting a narrower age range of 1–11 months. This trial assesses the efficacy of azithromycin MDA to 1–11-month-old children in reducing mortality...

Description complète

Détails bibliographiques

Auteurs principaux:	Thomas M Lietman, Ali Sie, Elodie Lebas, Mamadou Bountogo, Mamadou Ouattara, Boubacar Coulibaly, Kieran S O’Brien, Fanny Yago-Wienne, Issouf Bamba, Benjamin Arnold, Brittany Peterson, Valérie Zombré, Djeinam Toure, Georges Dimithé, Regina Khassanova, Souleymane Sidibé, Pouorinibé Noel Some
Format:	Artigo
Langue:	Inglês
Publié:	BMJ Publishing Group 2026-01-01
Collection:	BMJ Global Health
Accès en ligne:	https://gh.bmj.com/content/11/1/e021336.full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!